Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). - Wikidata - wikimedia - TriplyDB

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

http://www.wikidata.org/entity/Q34974362

about

Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview Novel strategies to target the ubiquitin proteasome system in multiple myeloma The 26S proteasome is a multifaceted target for anti-cancer therapies New molecular targets in mantle cell lymphoma New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites Clinical use of proteasome inhibitors in the treatment of multiple myeloma Trial Watch: Proteasomal inhibitors for anticancer therapy The ubiquitin proteasome system and myocardial ischemia Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Proteasome inhibitors in the treatment of multiple myeloma Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.Recent advances in proteasome inhibitor discovery.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Proteasome inhibitors in cancer therapy Molecular targeted approaches in mantle cell lymphoma.Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.The 26S proteasome complex: an attractive target for cancer therapy The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.Structure- and function-based design of Plasmodium-selective proteasome inhibitors The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.Regulation of the nucleocytoplasmic trafficking of viral and cellular proteins by ubiquitin and small ubiquitin-related modifiers.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.Inhibitors of the immunoproteasome: current status and future directions Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.Threonine peptidases as drug targets against malaria.Novel proteasome inhibitors to overcome bortezomib resistance.

P2860

Q26738752-D48F78B5-6F9F-4485-808E-EA48AB840F27 Q26773246-7CE70DFD-0C58-46CD-9603-8A34D9EC52F2 Q26795764-8DEC9FD8-FA34-4569-8A65-2FE0787A33F9 Q26821766-7D0847A7-8CD5-4D62-B44B-F49C90B59751 Q27004421-6F0E13C2-EDE8-4657-9453-014DDF9D5BAB Q27675903-E983CC02-0C76-4A97-91FD-EB437C4230D4 Q28080999-69F871D2-C9D4-4779-A33B-C5B31FF2B7D0 Q28082910-03576154-E457-4F24-A10E-4EA8BA2F376F Q28280898-86520DB5-2D15-4E35-B9C2-1EFD17DEDE4B Q33420278-CBCCF07B-2062-4E33-A12B-430A1D96907A Q34079904-3F548DBA-AF74-4F79-91F8-0768E568875D Q34119207-9BB7EB6F-6CCF-4FE0-8316-7E455BD6DFA7 Q34134986-A72CE3D2-C76F-4AB8-8B43-FBCC605CA78E Q34218976-11061ABB-4745-4073-872B-3C859A3D9BD7 Q34317307-759791E5-AAD6-48DC-9FB9-FADAAD571F68 Q34608271-CBE77030-4F40-43B1-A2EA-F0F49B8AF891 Q34611676-9ED96E4A-1605-4606-81F6-5347CF6D3FE2 Q34644848-F3C77936-5E76-4330-A255-FB2EACD66DD0 Q34645067-D8D9D6C0-FBE9-4791-A68A-FB0C0C2CA5C2 Q34773850-DEEA709F-F3C7-4382-A712-A3E4FA8E51AA Q34939959-B8A3E3A5-863B-4AEB-AC48-940E37E19720 Q35127368-13E1910F-20D1-4368-BC92-176E0208B8C0 Q35555565-ED76F989-CD0D-4CCA-B94C-669049495D9B Q35624079-8CC7AD48-8024-4089-A2A7-37D493947F57 Q35824929-2A22D4B1-D71D-4404-891E-B776BEAF97B2 Q35889653-B84ABC39-58FA-4985-B51C-DA091DC3DAF6 Q36008590-FD258E8F-56AF-430A-B918-02E0D9DDB36E Q36115692-083D7AA6-7446-434B-BF7A-F6B3C4FBEF58 Q36293871-D117D2F3-7065-493E-8C88-EE469891B123 Q36354644-6389D867-27AC-4386-B113-1E2E6F432C7D Q36584903-9900318C-6590-45DD-A01D-1B74E80334EB Q36709283-1565D53D-C7CF-406C-A965-AAA992751716 Q36763766-95D9A9DD-B596-44E7-8F52-9244C7D55E50 Q37017342-9036B869-E29F-4FF8-BE2F-0A5AA2EC6BD8 Q37166798-44BE3290-1907-4908-8688-A04DDD2E080A Q37252274-897A3680-4BD0-4402-9B39-38FFD28CBD32 Q37292307-A28EA2F1-7FA7-4CB8-81CC-1B9C2E02A50E Q37615678-A49C7E21-F934-4F02-9F0E-1101907C2477 Q37833642-45E5F684-7119-4F3E-8404-22E9FE379192 Q37878771-EEAFF420-51A3-4705-9575-BF282265C31E

P2860

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

http://www.wikidata.org/entity/Q34974362

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@ast

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@en

Design and synthesis of an ora ...... oxyketone proteasome inhibitor

@nl

type

label

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@ast

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@en

Design and synthesis of an ora ...... oxyketone proteasome inhibitor

@nl

prefLabel

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@ast

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@en

Design and synthesis of an ora ...... oxyketone proteasome inhibitor

@nl

P1433

Q34974362-8BB0A8BC-D849-439E-8496-306A8982FFC2

P1476

Q34974362-21475510-E4BB-48C7-B098-F0B23E6BCDDB

P2093

Q34974362-2F1EF82D-58D2-4668-B8B5-C11F8A18F259

Q34974362-3CB154C8-B13B-482D-8482-4260F317B37E

Q34974362-4115063D-06CF-4B9A-A7DA-1104CF9A608E

Q34974362-60122F1D-AF6F-44D5-A5A9-A5A1C267EC36

Q34974362-6074D699-CA2B-41D7-9AD4-17FC1ADA1C09

Q34974362-66B6AAD3-B336-4DF1-A5E5-5283DC0C3E0C

Q34974362-69C48F3D-1814-441E-A708-7115B9389397

Q34974362-77B347B2-F787-416B-9696-39844FA9827E

Q34974362-84AD6556-533C-442B-8DB2-29E12FFAA9F1

Q34974362-889D8BD4-64FF-4994-B66B-A47C91A6DF3B

P304

Q34974362-03E9AE64-A9D7-4FDF-B612-B8D8D5958739

P31

Q34974362-CE80771E-CA8E-4420-8F2E-FE6B5D6DD42F

P356

Q34974362-D55D98EC-AA01-48F7-89B4-7BF661310045

P407

Q34974362-6C4456D7-90C2-49CD-854F-98BFA44244D9

P433

Q34974362-8E273D09-0E82-4EDA-8AD2-FBA6CAF7799E

P478

Q34974362-8C7825D8-3BCD-4928-B3BC-1EE0E9503A0D

P577

Q34974362-73CD4E67-1EDB-4CAF-BB24-94ACE2514249

P698

Q34974362-078F0221-FB1A-44B1-91B6-ACCD4C6FECDD

P921

Q34974362-FFDBB536-ACBB-4BF4-8228-76427EAF598D

P356

P1433

Journal of Medicinal Chemistry

P1476

Design and synthesis of an ora ...... proteasome inhibitor (PR-047).

@en

P2093

Catherine Sylvain

http://www.w3.org/2001/XMLSchema#string

Christopher J Kirk

http://www.w3.org/2001/XMLSchema#string

Congcong M Sun

http://www.w3.org/2001/XMLSchema#string

Eileen Ring

http://www.w3.org/2001/XMLSchema#string

Evan R Lewis

http://www.w3.org/2001/XMLSchema#string

Francesco Parlati

http://www.w3.org/2001/XMLSchema#string

Guy J Laidig

http://www.w3.org/2001/XMLSchema#string

Han-Jie Zhou

http://www.w3.org/2001/XMLSchema#string

Jamie Shields

http://www.w3.org/2001/XMLSchema#string

Jinfu Yang

http://www.w3.org/2001/XMLSchema#string

P304

3028-3038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM801329V

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19348473

http://www.w3.org/2001/XMLSchema#string

P921